(Reuters) - The U.S. Food and Drug Administration has ordered Pfizer Inc to test the effects of an additional course of Paxlovid among people who experience a rebound in COVID-19 after treatment, Bloomberg News reported on Friday.
The company must produce initial results of a randomized controlled trial of a second course of the antiviral by Sept. 30 next year, the report said, citing a letter from the regulator to the company dated Aug. 5.
(Reporting by Leroy Leo in Bengaluru; Editing by Aditya Soni)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 25.4 USD | +0.55% | -2.31% | 143B | ||
